Benign Prostatic Hyperplasia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Benign Prostatic Hyperplasia stocks.

Benign Prostatic Hyperplasia Stocks Recent News

Date Stock Title
May 11 LLY 1 No-Brainer Growth Stock to Buy and Hold
May 11 LLY Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
May 10 LLY Lilly could partner with Cipla to market GLP-1 drugs in India - report
May 10 BSX Neogen (NEOG) Faces Macroeconomic Issues, Fierce Competition
May 10 LLY Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
May 10 BSX AMN Healthcare (AMN) Q1 Earnings and Revenues Beat Estimates
May 10 BSX PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up
May 10 LLY One in eight U.S. adults admits to GLP-1 usage as public awareness climbs
May 10 LLY Dividend Roundup: Eli Lilly, American Express, Microsoft, Delta Air Lines, and more
May 10 LLY How A Top Fund Beats The Market By Owning Future Leaders
May 10 LLY Innovent’s mazdutide superior to Trulicity in Phase III T2D trial
May 10 LLY Zacks Investment Ideas feature highlights: Eaton, Eli Lilly and Arista Networks
May 10 LLY UPDATE 2-India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says
May 9 LLY 3 Stocks to Buy Following Guidance Upgrades
May 9 LLY Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2024 Earnings Call Transcript
May 9 BSX Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up
May 9 BSX Inogen (INGN) Q1 Earnings Top Estimates, Revenues Up Y/Y
May 9 BSX QuidelOrtho (QDEL) Q1 Earnings Beat Estimates, Margins Fall
May 9 LLY Lilly next-generation diabetes drug mazdutide meets primary goal in phase 3 trial
May 9 BSX OPKO Health's (OPK) Q1 Earnings Miss Estimates, Sales Down Y/Y
Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems.The cause is unclear. Risk factors include a family history, obesity, type 2 diabetes, not enough exercise, and erectile dysfunction. Medications like pseudoephedrine, anticholinergics, and calcium channel blockers may worsen symptoms. The underlying mechanism involves the prostate pressing on the urethra thereby making it difficult to pass urine out of the bladder. Diagnosis is typically based on symptoms and examination after ruling out other possible causes.Treatment options including lifestyle changes, medications, a number of procedures, and surgery. In those with mild symptoms weight loss, exercise, and decreasing caffeine intake is recommended. In those with more significant symptoms medications may include alpha blockers such as terazosin or 5α-reductase inhibitors such as finasteride. Surgical removal of part of the prostate may be carried out in those who do not improve with other measures. Alternative medicine, such as saw palmetto, does not appear to help.About 105 million people are affected globally. BPH typically begins after the age of 40. Half of males age 50 and over are affected. After the age of 80 about 90% of males are affected. Although prostate specific antigen levels may be elevated in males with BPH, the condition does not increase the risk of prostate cancer.

Browse All Tags